Mastodon

Momaid (Ointment, Cream) Instructions for Use

ATC Code

D07AC13 (Mometasone)

Active Substance

Mometasone (Rec.INN registered by WHO)

Clinical-Pharmacological Group

Topical corticosteroids for external use

Pharmacotherapeutic Group

Topical glucocorticosteroid

Pharmacological Action

Glucocorticosteroid for external use. It has anti-inflammatory, antipruritic, and anti-exudative effects.

Glucocorticosteroids induce the release of proteins that inhibit phospholipase A2, known collectively as lipocortins, which control the biosynthesis of inflammatory mediators such as prostaglandins and leukotrienes by inhibiting the release of their common precursor, arachidonic acid.

Pharmacokinetics

Absorption of the drug after topical application is minimal. Eight hours after application to intact skin (without an occlusive dressing), 0.7% of mometasone is detected in the systemic circulation.

Indications

Inflammatory reactions and itching in dermatoses amenable to glucocorticosteroid therapy.

ICD codes

ICD-10 code Indication
L20.8 Other atopic dermatitis (neurodermatitis, eczema)
L23 Allergic contact dermatitis
L24 Irritant contact dermatitis
L28.0 Lichen simplex chronicus (circumscribed neurodermatitis)
L29 Pruritus
L30.0 Nummular eczema
L30.9 Dermatitis, unspecified
ICD-11 code Indication
9A06.70 Atopic eczema of the eyelids
EA80.0 Infantile atopic eczema
EA80.1 Childhood atopic eczema
EA80.2 Adult atopic eczema
EA80.Z Atopic eczema, unspecified
EA82 Nummular dermatitis
EA83.00 Lichen simplex of vulva
EA83.01 Lichen simplex of male genital organs
EA83.02 Lichen simplex of perianal area
EA83.0Z Lichen simplex of unspecified location
EA85.20 Atopic hand eczema
EA85.2Z Hand dermatitis, unspecified
EA85.3 Foot dermatitis
EA89 Generalized eczematous dermatitis of unspecified type
EA8Z Dermatitis or eczema, unspecified
EC90.Z Itching, unspecified
EK00.Z Allergic contact dermatitis, unspecified
EK02.Z Irritant contact dermatitis, unspecified

Dosage Regimen

The method of application and dosage regimen for a specific drug depend on its form of release and other factors. The optimal dosage regimen is determined by the doctor. It is necessary to strictly adhere to the compliance of the dosage form of a specific drug with the indications for use and dosage regimen.

Apply a thin layer of Momaid ointment or cream to the affected skin areas once daily.

Gently rub in the medication until it is fully absorbed. Avoid application on broken skin, near the eyes, or on mucous membranes.

Use the minimum amount necessary to control symptoms. Do not cover the treated area with occlusive dressings unless specifically directed by a physician.

For adults and children 2 years and older, treatment duration should be as short as possible. Do not exceed continuous use for more than 4 weeks.

Re-evaluate the patient if no clinical improvement is observed within 2 weeks. Discontinue use once control of the dermatosis is achieved.

For pediatric patients, limit the total application area and avoid long-term use due to higher risk of systemic absorption and hypothalamic-pituitary-adrenal (HPA) axis suppression.

When discontinuing after prolonged therapy, gradually reduce the frequency of application to prevent rebound dermatitis.

Adverse Reactions

Infections and infestations rarely – folliculitis, secondary infection.

Skin and subcutaneous tissue disorders rarely – skin irritation and dryness, burning sensation, itching, hypertrichosis, acne, hypopigmentation, perioral dermatitis, allergic contact dermatitis, secondary infection, skin maceration, signs of skin atrophy, striae, miliaria, formation of papules, pustules.

Nervous system disorders frequency not established – paresthesia.

When using topical glucocorticosteroid forms for a long time and/or for treating large areas of skin, or with the use of occlusive dressings, especially in children and adolescents, side effects characteristic of systemic glucocorticosteroids may occur, including adrenal insufficiency and Cushing’s syndrome.

Contraindications

Hypersensitivity to mometasone; rosacea; perioral dermatitis; bacterial, viral (Herpes simplex, Herpes zoster, chickenpox), fungal skin infection; tuberculosis; syphilis; post-vaccination reactions; pregnancy (application to large areas of skin, long-term treatment); lactation period (use in high doses and/or for a long time); children under 2 years of age.

With caution should be applied to the skin of the face and intertriginous skin, use occlusive dressings, and also apply to large areas of skin and/or for a long time (especially in children).

Use in Pregnancy and Lactation

Contraindicated for use during pregnancy on large areas of skin, for a long time; during breastfeeding.

Pediatric Use

Contraindication: children under 2 years of age.

Special Precautions

When applied to large areas of skin for a long time, especially when using occlusive dressings, the development of systemic effects of glucocorticosteroids is possible. Given this, patients should be monitored for signs of suppression of the hypothalamic-pituitary-adrenal system function and the development of Cushing’s syndrome.

It should be taken into account that glucocorticosteroids can alter the manifestations of some skin diseases, which may complicate diagnosis. Furthermore, the use of glucocorticosteroids can cause delayed wound healing.

During long-term glucocorticosteroid therapy, sudden discontinuation of therapy can lead to the development of a rebound syndrome, manifested as dermatitis with intense skin redness and a burning sensation. Therefore, after a long course of treatment, the drug should be discontinued gradually, for example, by switching to an intermittent treatment regimen before stopping it completely.

Any of the side effects described with systemic use of glucocorticosteroids, including adrenal suppression, can also occur with topical use, especially in children.

Use in pediatrics

Because the ratio of surface area to body weight is greater in children than in adults, children are at greater risk of suppression of the hypothalamic-pituitary-adrenal system function and the development of Cushing’s syndrome when using any topical glucocorticosteroids. Long-term use of glucocorticosteroids in children can lead to impairments in their growth and development.

In children, it should be used in the minimum effective dose.

Storage Conditions

Store at 2°C (36°F) to 25°C (77°F). Keep in original packaging, protected from light. Keep out of reach of children.

Dispensing Status

Rx Only

Important Safety Information

This information is for educational purposes only and does not replace professional medical advice. Always consult your doctor before use. Dosage and side effects may vary. Use only as prescribed.

Medical Disclaimer

Brand (or Active Substance), Marketing Authorisation Holder, Dosage Form

Marketing Authorization Holder

Glenmark Pharmaceuticals, Ltd. (India)

Dosage Form

Bottle Rx Icon Momaid Cream for external use 0.1%: tubes 5 g or 15 g

Dosage Form, Packaging, and Composition

Cream for external use white in color.

100 g
Mometasone furoate 0.1 g

Excipients : paraffin (soft white paraffin), white beeswax, propylene glycol monostearate, stearyl alcohol, cetomacrogol, propylene glycol, methylparahydroxybenzoate, propylparahydroxybenzoate, purified water.

5 g – aluminum tubes (1) – cardboard boxes.
15 g – aluminum tubes (1) – cardboard boxes.

Marketing Authorization Holder

Glenmark Pharmaceuticals, Ltd. (India)

Dosage Form

Bottle Rx Icon Momaid Ointment for external use 0.1%: tubes 5 g or 15 g

Dosage Form, Packaging, and Composition

Ointment for external use white in color.

100 g
Mometasone furoate 0.1 g

Excipients : paraffin (soft white paraffin), white beeswax, propylene glycol monostearate.

5 g – aluminum tubes (1) – cardboard boxes.
15 g – aluminum tubes (1) – cardboard boxes.

TABLE OF CONTENTS